Trial Profile
A Phase 2b, Randomized, Partially Blind (Open Label Warfarin), Active-Controlled (Warfarin), Multicenter Study, To Evaluate The Safety And Efficacy In 2 Doses Of Apixaban In Comparison To Warfarin, Administered For 12 Weeks In Subjects With NVAF.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Warfarin
- Indications Thrombosis
- Focus Adverse reactions
- Sponsors Pfizer
- 09 Oct 2009 Actual end date (Sep 2009), actual number of patients (222) added as reported by ClinicalTrials.gov.
- 09 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Nov 2008 New trial record.